How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for fixed ratio combinations such as iGlarLixi and iDegLira?

How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for fixed ratio combinations such as iGlarLixi and iDegLira?

How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for the safety and efficacy of fixed ratio combinations such as iGlarLixi and iDegLira?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Derek LeRoith, MD, PhD

Derek LeRoith, MD, PhD

Professor of Medicine Director of Research in the Division of Endocrinology, Diabetes and Bone Diseases Mount Sinai School of Medicine New York, New York